Should You Invest in Lam Research Stock Despite Its Premium Valuation?

Lam Research’s fiscal Q4 2026 revenue rose 30% year over year to $6.72B and non-GAAP EPS increased 37% to $1.82, beating consensus by 0.7% and 7.7%, respectively; gross margin expanded 170 bps to 35%. The article argues that earnings growth, AI-related semiconductor investment and expected advanced-packaging revenue growth of more than 70% in 2026 support LRCX’s premium valuation, despite its 33.83 forward P/E versus the industry average of 14.24. Zacks estimates fiscal 2027 revenue and EPS growth of 47.2% and 60.4%, respectively.

Analysis

The key debate is not whether AI raises demand for wafer-fab equipment, but whether Lam can convert that demand into durable, incremental earnings quickly enough to outrun expectations. The reported advanced-packaging growth rate is a weak valuation anchor without its starting revenue base and contribution to total profit; investors should not capitalize a high growth rate as though it were already material. More consequential is whether customers sustain equipment budgets across leading-edge logic and HBM after the current buildout. A pause or mix shift could expose LRCX to the usual capex-cycle multiple compression even if long-run process intensity keeps rising.

Competitive read-through is mixed: etch/deposition intensity may support LRCX, while AMAT offers a plausible relative-value alternative; ASML’s lithography exposure is not a clean substitute. Customer concentration in major fabs also means AI demand is mediated by a small number of capital-allocation decisions, not end-market enthusiasm alone. The article’s estimates and company growth claims need validation against orders, customer capex plans, and segment-level packaging revenue.

Near term, strong results may sustain momentum, but the large prior rerating leaves less room for guidance merely to meet elevated growth expectations. Over 1–3 months, watch order trends, fiscal guidance, and customer capex updates; over 6–18 months, the test is whether new process steps and packaging translate into recurring, material sales. Contrarian angle: the structural story may be right while the stock’s risk/reward is less attractive than the industry narrative suggests.

Key Decisions for Investors

• Avoid chasing LRCX after the sharp rerating; consider initiating only on weakness or after evidence that orders and guidance support the growth path. The thesis is falsified by a material guidance reduction, order deterioration, or customer capex pullbacks.
• For a relative-value expression, consider a modest LRCX underweight versus AMAT rather than an outright semiconductor-equipment short: the article indicates a valuation premium for LRCX, but does not establish that its earnings outlook is inferior. Reassess if LRCX sustains superior order growth or AMAT’s relative performance reverses.
• Treat advanced-packaging growth as an alert, not a standalone buy signal. Verify its revenue/profit contribution and customer adoption before assigning it meaningful valuation weight; a high percentage increase from a small base would not offset weakness in core equipment demand.
• Monitor TSM and Samsung capex commentary, HBM/packaging capacity additions, and LRCX order or backlog trends as catalysts. A broad capex pause is the principal downside risk; continued spending accompanied by estimate upgrades would weaken the cautious relative-value view.